JPH0355446B2 - - Google Patents
Info
- Publication number
- JPH0355446B2 JPH0355446B2 JP634983A JP634983A JPH0355446B2 JP H0355446 B2 JPH0355446 B2 JP H0355446B2 JP 634983 A JP634983 A JP 634983A JP 634983 A JP634983 A JP 634983A JP H0355446 B2 JPH0355446 B2 JP H0355446B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- fuenvalerate
- application
- facial
- paresthesia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 57
- 229930003427 Vitamin E Natural products 0.000 claims description 28
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 28
- 229940046009 vitamin E Drugs 0.000 claims description 28
- 239000011709 vitamin E Substances 0.000 claims description 28
- 235000019165 vitamin E Nutrition 0.000 claims description 28
- 208000035824 paresthesia Diseases 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000002728 pyrethroid Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 3
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 239000011550 stock solution Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 4
- 229940066842 petrolatum Drugs 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000005946 Cypermethrin Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 2
- 229960005424 cypermethrin Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- OYDPVRNLLQZQFY-UHFFFAOYSA-N 2,2-dimethyl-3-[(2-oxothiolan-3-ylidene)methyl]cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1C(C)(C)C1C=C1C(=O)SCC1 OYDPVRNLLQZQFY-UHFFFAOYSA-N 0.000 description 1
- CDULGHZNHURECF-UHFFFAOYSA-N 2,3-dimethylaniline 2,4-dimethylaniline 2,5-dimethylaniline 2,6-dimethylaniline 3,4-dimethylaniline 3,5-dimethylaniline Chemical group CC1=CC=C(N)C(C)=C1.CC1=CC=C(C)C(N)=C1.CC1=CC(C)=CC(N)=C1.CC1=CC=C(N)C=C1C.CC1=CC=CC(N)=C1C.CC1=CC=CC(C)=C1N CDULGHZNHURECF-UHFFFAOYSA-N 0.000 description 1
- VTJMSIIXXKNIDJ-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-methylbutyric acid Chemical compound CC(C)C(C(O)=O)C1=CC=C(Cl)C=C1 VTJMSIIXXKNIDJ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- XQUXKZZNEFRCAW-UHFFFAOYSA-N fenpropathrin Chemical compound CC1(C)C(C)(C)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 XQUXKZZNEFRCAW-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP634983A JPS59130815A (ja) | 1983-01-17 | 1983-01-17 | 顔面錯感覚症予防および治療薬 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP634983A JPS59130815A (ja) | 1983-01-17 | 1983-01-17 | 顔面錯感覚症予防および治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59130815A JPS59130815A (ja) | 1984-07-27 |
| JPH0355446B2 true JPH0355446B2 (enExample) | 1991-08-23 |
Family
ID=11635890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP634983A Granted JPS59130815A (ja) | 1983-01-17 | 1983-01-17 | 顔面錯感覚症予防および治療薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59130815A (enExample) |
-
1983
- 1983-01-17 JP JP634983A patent/JPS59130815A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59130815A (ja) | 1984-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lauritzen et al. | The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression | |
| DE69431729T2 (de) | Bromocryptin enthaltende mittel mit beschleunigter freisetzung | |
| DE69017596T2 (de) | Verwendung eines Opiatantagonisten zur Herstellung eines transdermal zu verabreichenden Arzneimittels sowie eine Vorrichtung zur transdermalen Verabreichung. | |
| Sherman et al. | A neuropharmacologically-relevant animal model of depression | |
| DE69432027T2 (de) | Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren | |
| Awerbuch et al. | Mexiletine for thalamic pain syndrome | |
| FI955782A0 (fi) | Menetelmä kivun käsittelemiseksi 24-tunnin suun kautta annettavia opioidiformulointeja, joilla saadaan lääkkeen plasmatason nopea alkunousu | |
| Duysens et al. | Gait acts as a gate for reflexes from the foot | |
| WO1998008546A3 (en) | Therapeutic combinations of rar antagonists and rxr agonists and use thereof | |
| CA2289093A1 (en) | Use of melatonin for preparing medicaments for treating circadian rhythm phase disorders | |
| CN102143687B (zh) | 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途 | |
| EP1210081A2 (de) | Wirkstoffkombination enthaltend clonidin und pramipexol | |
| Pepeu et al. | The relationship between the behavioral effects of cognition-enhancing drugs and brain acetylcholine | |
| Matson et al. | A comparison of DRO to movement suppression time-out and DRO with two self-injurious and aggressive mentally retarded adults | |
| Obeso et al. | Dopamine agonists suppress visual-cortical reflex myoclonus. | |
| Schwartz et al. | Chronic electrical stimulation reverses deafness-related depression of electrically evoked 2-deoxyglucose activity in the guinea pig inferior colliculus | |
| Thomsen et al. | Topically applied aspirin decreases histamine-induced wheal and flare reactions in normal and SLS-inflamed skin, but does not decrease itch. A randomized, double-blind and placebo-controlled human study | |
| Houser et al. | The effects of scopolamine and pilocarpine upon the aversive threshold of the rat | |
| Vazquez et al. | The effects of sensory stimulation on REM sleep duration | |
| Natelson et al. | The role of shock predictability during aversive conditioning in producing psychosomatic digitalis toxicity | |
| Hasson et al. | Effect of iontophoretically delivered dexamethasone on muscle performance in a rheumatoid arthritic joint. A case study | |
| JPS59130815A (ja) | 顔面錯感覚症予防および治療薬 | |
| JPS5993018A (ja) | 顔面錯感覚症治療薬 | |
| US4575506A (en) | Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics | |
| Liebetanz et al. | Pharmacology of transcranial direct current stimulation: missing effect of riluzole |